Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Pharmacogenetically driven treatments for alcoholism: are we there yet?

Arias AJ, Sewell RA.

CNS Drugs. 2012 Jun 1;26(6):461-76. doi: 10.2165/11633180-000000000-00000. Review.

PMID:
22587755
2.

Pharmacogenetics of alcohol and alcohol dependence treatment.

Kranzler HR, Edenberg HJ.

Curr Pharm Des. 2010;16(19):2141-8. Review.

3.

Genetic moderators of naltrexone's effects on alcohol cue reactivity.

McGeary JE, Monti PM, Rohsenow DJ, Tidey J, Swift R, Miranda R Jr.

Alcohol Clin Exp Res. 2006 Aug;30(8):1288-96.

PMID:
16899031
4.

Ondansetron and sertraline may interact with 5-HTTLPR and DRD4 polymorphisms to reduce drinking in non-treatment seeking alcohol-dependent women: exploratory findings.

Kenna GA, Zywiak WH, Swift RM, McGeary JE, Clifford JS, Shoaff JR, Fricchione S, Brickley M, Beaucage K, Haass-Koffler CL, Leggio L.

Alcohol. 2014 Sep;48(6):515-22. doi: 10.1016/j.alcohol.2014.04.005.

5.

Opioid pharmacogenetics of alcohol addiction.

Berrettini W.

Cold Spring Harb Perspect Med. 2013 Jul 1;3(7). pii: a012203. doi: 10.1101/cshperspect.a012203. Review.

6.

Interacting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues.

Schacht JP, Anton RF, Voronin KE, Randall PK, Li X, Henderson S, Myrick H.

Neuropsychopharmacology. 2013 Feb;38(3):414-22. doi: 10.1038/npp.2012.195.

7.

The role of the Asn40Asp polymorphism of the mu opioid receptor gene (OPRM1) on alcoholism etiology and treatment: a critical review.

Ray LA, Barr CS, Blendy JA, Oslin D, Goldman D, Anton RF.

Alcohol Clin Exp Res. 2012 Mar;36(3):385-94. doi: 10.1111/j.1530-0277.2011.01633.x. Review.

8.

Personalized treatment of alcohol dependence.

Kranzler HR, McKay JR.

Curr Psychiatry Rep. 2012 Oct;14(5):486-93. doi: 10.1007/s11920-012-0296-5. Review.

PMID:
22810115
9.

Alcohol addiction and the mu-opioid receptor.

Berrettini W.

Prog Neuropsychopharmacol Biol Psychiatry. 2016 Feb 4;65:228-33. doi: 10.1016/j.pnpbp.2015.07.011. Review.

PMID:
26226591
10.
11.

Study suggests gene may predict success of therapies for alcohol dependence.

Kuehn BM.

JAMA. 2011 Mar 9;305(10):984-5. doi: 10.1001/jama.2011.270. No abstract available.

PMID:
21386072
12.

Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study.

Gelernter J, Gueorguieva R, Kranzler HR, Zhang H, Cramer J, Rosenheck R, Krystal JH; VA Cooperative Study #425 Study Group..

Alcohol Clin Exp Res. 2007 Apr;31(4):555-63.

PMID:
17374034
13.
14.

Pharmacogenetics of naltrexone and disulfiram in alcohol dependent, dually diagnosed veterans.

Arias AJ, Gelernter J, Gueorguieva R, Ralevski E, Petrakis IL.

Am J Addict. 2014 May-Jun;23(3):288-93. doi: 10.1111/j.1521-0391.2014.12102.x.

15.

Polymorphisms of the mu-opioid receptor and dopamine D4 receptor genes and subjective responses to alcohol in the natural environment.

Ray LA, Miranda R Jr, Tidey JW, McGeary JE, MacKillop J, Gwaltney CJ, Rohsenow DJ, Swift RM, Monti PM.

J Abnorm Psychol. 2010 Feb;119(1):115-25. doi: 10.1037/a0017550.

16.

The μ-opioid receptor and treatment response to naltrexone.

Thorsell A.

Alcohol Alcohol. 2013 Jul-Aug;48(4):402-8. doi: 10.1093/alcalc/agt030. Review.

17.

Pharmacogenetics of OPRM1.

Crist RC, Berrettini WH.

Pharmacol Biochem Behav. 2014 Aug;123:25-33. doi: 10.1016/j.pbb.2013.10.018. Review.

18.

COMBINE genetics study: the pharmacogenetics of alcoholism treatment response: genes and mechanisms.

Goldman D, Oroszi G, O'Malley S, Anton R.

J Stud Alcohol Suppl. 2005 Jul;(15):56-64; discussion 33. Review.

PMID:
16223057
19.

A within-group design of nontreatment seeking 5-HTTLPR genotyped alcohol-dependent subjects receiving ondansetron and sertraline.

Kenna GA, Zywiak WH, McGeary JE, Leggio L, McGeary C, Wang S, Grenga A, Swift RM.

Alcohol Clin Exp Res. 2009 Feb;33(2):315-23. doi: 10.1111/j.1530-0277.2008.00835.x.

PMID:
19032576
20.

Naltrexone modification of drinking effects in a subacute treatment and bar-lab paradigm: influence of OPRM1 and dopamine transporter (SLC6A3) genes.

Anton RF, Voronin KK, Randall PK, Myrick H, Tiffany A.

Alcohol Clin Exp Res. 2012 Nov;36(11):2000-7. doi: 10.1111/j.1530-0277.2012.01807.x.

Items per page

Supplemental Content

Support Center